Tempest Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-26.3M | $-41.8M | $-29.5M | $-35.7M | $-28.3M | $-19.2M | $-44.6M | $-27.2M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $266.0K | $389.0K | $381.0K | $638.0K | $374.0K | $339.0K | $97.0K | $32.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | — | — | — | — | — | — | — | — |
| Net Cash from Operating Activities | $-26.8M | $-33.0M | $-27.4M | $-31.1M | $-26.0M | $-19.0M | $-41.2M | $-23.6M |
| Investing Activities | ||||||||
| Capital Expenditures | $0 | $435.0K | $170.0K | $562.0K | $135.0K | $50.0K | $397.0K | $36.0K |
| Business Acquisitions | — | — | — | — | — | — | $0 | $524.0K |
| Net Cash from Investing Activities | $0 | $-435.0K | $-170.0K | $-562.0K | $-97.0K | $-6.0K | $4.0M | $1.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $4.3M | $24.5M | $35.6M | $11.4M | $59.1M | $34.6M | $26.9M | $77.7M |
| Net Change in Cash | — | — | — | — | — | $-24.9M | $-10.3M | $56.1M |
| Free Cash Flow | $-26.8M | $-33.5M | $-27.5M | $-31.6M | $-26.1M | $-19.1M | $-41.6M | $-23.7M |